Gigantism and acromegaly are essentially the same disease. Both are caused by excessive growth hormone, both trigger the same cascade of tissue and bone overgrowth, and both carry the same long-term health risks. The only thing that separates them is timing: whether the growth hormone excess begins before or after a child’s growth plates have fused.
The Same Cause, Different Timing
In both conditions, the problem almost always starts with a benign tumor on the pituitary gland, a pea-sized structure at the base of the brain that controls hormone production. These tumors, called pituitary adenomas, account for about 15% of all intracranial tumors. When the tumor develops in the cells responsible for producing growth hormone (called somatotroph cells), it pumps out far more growth hormone than the body needs. That excess growth hormone also drives up levels of a second hormone, IGF-1, which is the molecule that directly stimulates bone and tissue growth throughout the body.
If this overproduction starts during childhood or adolescence, while the long bones can still lengthen, the result is gigantism. The child grows unusually tall because their growth plates (the cartilage zones near the ends of bones) are still open and responsive. If the same overproduction begins after puberty, once those growth plates have permanently fused, height can no longer increase. Instead, the excess hormones cause bones to thicken and soft tissues to enlarge, producing the characteristic features of acromegaly.
Researchers describe the two conditions as a continuum rather than separate diseases. Most people with gigantism eventually develop acromegalic features like enlarged hands and a prominent jaw. And many adults diagnosed with acromegaly are taller than average, suggesting their growth hormone excess may have started subtly before their growth plates closed.
Shared Physical Changes
The visible effects of excess growth hormone overlap heavily between the two conditions. In both gigantism and acromegaly, the hands and feet enlarge noticeably. Facial bones thicken, producing a jutting brow and a prominent lower jaw. The nose broadens, the lips and ears become thicker, and the tongue can enlarge enough to affect speech and breathing. These changes happen gradually, often over years, which is one reason both conditions are frequently diagnosed late.
In gigantism, these soft tissue and facial changes happen alongside dramatic increases in height. In acromegaly, height stays the same but the skeletal and soft tissue changes can be just as pronounced. People with either condition may notice that rings no longer fit, shoes need to be replaced with larger sizes, or their bite has shifted because their jaw has grown forward.
The Same Health Risks
The cardiovascular and metabolic complications are nearly identical in both conditions, because the underlying hormone excess is the same. Prolonged exposure to high growth hormone and IGF-1 levels causes the heart muscle to thicken and stiffen, a condition known as acromegalic cardiomyopathy. This is one of the leading causes of serious illness and death in both groups.
The hormonal excess also expands fluid volume in the body, promotes sodium and water retention, and increases blood vessel resistance, all of which drive up blood pressure. Hypertension affects anywhere from 18% to 77% of patients depending on how long the disease has been active. Abnormal heart rhythms, including dangerous ventricular arrhythmias, are more common as well, likely because of structural changes in the heart’s left ventricle.
Metabolic problems are equally shared. Between 22% and 77% of patients develop type 2 diabetes, with another 26% to 41% falling into the prediabetes range. Abnormal cholesterol and triglyceride levels affect up to 61% of patients. Sleep apnea is common in both conditions, driven by the enlargement of soft tissues in the airway and tongue.
Identical Diagnostic Testing
Doctors use the same test to confirm either condition: a growth hormone suppression test. You drink a sugary solution, and your blood is tested to see whether growth hormone levels drop in response. In a healthy person, the sugar load pushes growth hormone below 1 ng/mL. In someone with gigantism or acromegaly, growth hormone stays stubbornly elevated because the pituitary tumor keeps producing it regardless of what the rest of the body signals. Blood levels of IGF-1 are also measured, since this hormone stays elevated around the clock and gives a more stable picture than growth hormone, which naturally fluctuates throughout the day.
Shared Genetic Roots
The same genetic mutations can cause either condition depending on when in life the tumor forms. Over the past two decades, researchers have identified several inherited syndromes that predispose people to growth hormone-secreting pituitary tumors. These include multiple endocrine neoplasia types 1 and 4, Carney complex, McCune-Albright syndrome, and familial isolated pituitary adenoma (linked to mutations in a tumor suppressor gene called AIP). A more recently discovered condition called X-linked acrogigantism, or X-LAG, involves duplications on the X chromosome and tends to cause very early-onset gigantism.
These genetic causes are especially relevant in younger patients. Most cases of gigantism and acromegaly diagnosed in children, adolescents, and young adults trace back to one of these inherited conditions. The same mutation in the same family can produce gigantism in one member and acromegaly in another, depending purely on when the tumor starts secreting excess hormone.
The Same Treatment Approach
Because the underlying problem is identical, treatment follows the same playbook for both conditions. The first-line approach is surgical removal of the pituitary tumor, typically performed through the nose and sinuses to reach the base of the skull without opening it. At experienced surgical centers, long-term remission rates average around 80%, climbing to roughly 90% when the tumor is small and well-defined. Success means growth hormone and IGF-1 levels return to normal, which halts further tissue overgrowth, though some changes (like bone enlargement) are permanent.
When surgery doesn’t fully normalize hormone levels, or when tumors are too large to remove completely, medications that mimic a natural brain chemical called somatostatin become the primary treatment. These drugs suppress growth hormone production and can also shrink the tumor. They’re available as monthly injections or, more recently, as oral capsules that have shown consistent ability to keep growth hormone and IGF-1 in the normal range.
For both conditions, controlling the hormone excess also means managing the downstream health problems. Blood pressure, blood sugar, cholesterol, and sleep apnea all need ongoing attention, because the cardiovascular damage from years of elevated growth hormone doesn’t reverse automatically once hormone levels normalize. The earlier treatment begins, the less cumulative damage these complications cause, which is one reason early recognition of either condition matters so much.